Cipher Pharmaceuticals to present at Biotech Showcase™ 2013

Toronto Stock Exchange Symbol: DND

MISSISSAUGA, ON, Jan. 3, 2013 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND) (OTC: CPHMF), announced today that Larry Andrews, President and Chief Executive Officer, is presenting at Biotech Showcase™ 2013, which is being held in San Francisco at the Wyndham Parc 55 Hotel at Union Square. Mr. Andrews will provide a corporate update on Monday, January 7, 2013 at 1:45 PM PST in the Powell Room, followed immediately by Q&A breakout session in the Balboa Room.

To learn more about Biotech Showcase™ 2013 please visit their website http://bit.ly/134duey

Cipher's presentation will be available on their website www.cipherpharma.com.

About Cipher Pharmaceuticals Inc.

Cipher Pharmaceuticals (TSX: DND; OTC: CPHMF) is a growing specialty pharmaceutical company that commercializes novel formulations of successful, currently marketed molecules. Cipher's strategy is to in-license clearly differentiated products, advance them through the clinical development and regulatory approval stages, and out-license to international marketing partners. Cipher's first product is a fenofibrate formulation marketed in the United States as Lipofen®. Cipher's second product, an extended-release tramadol, is marketed in the United States as ConZip® and in Canada as Durela®. Cipher's third product, a novel formulation of the acne treatment isotretinoin, was approved by the FDA in May and was launched in the United States in Q4 2012 as Absorica™. The product was also recently approved by Health Canada and Cipher expects to launch it as Epuris™ in Canada in Q2 2013.

For more information, please visit www.cipherpharma.com.

SOURCE: Cipher Pharmaceuticals Inc.

Craig Armitage
Investor Relations
The Equicom Group
[phone] ext 278
[phone] fax
[email protected]

Larry Andrews
President and CEO
Cipher Pharmaceuticals
[phone] ext 324
[phone] fax
[email protected]